Curis Inc
CUS0
Company Profile
Business description
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Contact
128 Spring Street
Building C - Suite 500
LexingtonMA02421
USAT: +1 617 503-6500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
33
Stocks News & Analysis
stocks
Looking for growth outside the ASX100
Small caps have outperformed blue chips this year. Here’s some opportunities outside the ASX100.
stocks
Netflix and Warner Bros. Discovery: Surprisingly high merger price alters shareholder value for both
Our view on the blockbuster merger.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,898.00 | 9.10 | 0.10% |
| CAC 40 | 8,114.74 | 7.29 | -0.09% |
| DAX 40 | 24,028.14 | 146.11 | 0.61% |
| Dow JONES (US) | 47,954.99 | 104.05 | 0.22% |
| FTSE 100 | 9,667.01 | 43.86 | -0.45% |
| HKSE | 25,986.82 | 98.26 | -0.38% |
| NASDAQ | 23,578.13 | 72.99 | 0.31% |
| Nikkei 225 | 50,395.14 | 96.73 | -0.19% |
| NZX 50 Index | 13,526.19 | 42.20 | 0.31% |
| S&P 500 | 6,870.40 | 13.28 | 0.19% |
| S&P/ASX 200 | 8,608.00 | 12.40 | 0.14% |
| SSE Composite Index | 3,908.25 | 5.45 | 0.14% |